There have been positive results for Novartis’ Cosentyx® (secukinumab) treatment for polymyalgia rheumatica (PMR), where all primary and secondary endpoints in the phase 3 REPLENISH trial were achieved.
Cosentyx® is an interleukin-17A (IL-17A) inhibitor already approved for several inflammatory conditions, including psoriatic arthritis.
The phase 3 study evaluated the safety and efficacy of in patients with PMR, with participants across 27 countries assigned to one of three treatment arms – Cosentyx® 150mg, Cosentyx® 300mg, or placebo – in combination with a 24-week steroid tapering regimen.
At Week 52, the report found that Cosentyx® met its primary endpoint, demonstrating statistically significant and clinically meaningful sustained remission compared with placebo. All secondary endpoints were also met, including the proportion of patients achieving complete sustained remission at Week 52, the adjusted annual cumulative corticosteroid dose, and the time to first use of escape or rescue therapy.
Angelika Jahreis, Global Head, Immunology Development, Novartis, said: “PMR is an inflammatory rheumatic disease characterised by bilateral pain of the neck, shoulders or hips, morning stiffness and fatigue. It tends to flare and significantly impact patients’ quality of life. These results highlight the potential of Cosentyx® to help patients achieve and sustain disease remission and reduce corticosteroids, which can lead to significant side effects in this typically elderly patient population. Today’s results represent another breakthrough in transforming care in rheumatology.”




